|
See related Isentress tab information |
|
|
|
Manufacturer |
MSD |
|
Distributor |
Hong Kong: DKSH |
|
Contents |
Raltegravir |
|
Indications |
In combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients. |
|
Dosage |
400 mg bd. Co-administration w/ rifampin 800 mg bd. |
|
Administration |
May be taken with or without food |
|
Contraindications |
Hypersensitivity. |
|
Special Precautions |
Patients w/ a history of myopathy or rhabdomyolysis. Elderly. Risk of immune reconstitution syndrome in patients responding to antiretroviral therapy during the initial phase of treatment. Pregnancy & lactation. |
|
Adverse Drug Reactions |
Diarrhea, nausea, headache, nasopharyngitis, bronchitis, vomiting, asthenia, pyrexia, fatigue, upper resp tract infections.
View ADR Monitoring Form |
|
Drug Interactions |
Strong inducers of uridine diphosphate glucuronosyltransferase (UGT) 1A1 eg rifampin. Drugs that are known to increase gastric pH (eg proton-pump inhibitor).
View more drug interactions with Isentress |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
ATC Classification |
J05AX08 - raltegravir ; Belongs to the class of other antivirals. Used as a direct acting antiviral in the systemic treatment of viral infections. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Isentress tablet |
|
|
|
Manufacturer: |
MSD |
|
Distributor: |
Hong Kong: DKSH |
|
 |
 |
|
|
